Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) released its quarterly earnings results on Tuesday. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19, FiscalAI reports. The business had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%.

Kiniksa Pharmaceuticals International Price Performance

KNSA opened at $72.98 on Tuesday. The business has a 50-day moving average of $78.03 and a 200-day moving average of $59.00. Kiniksa Pharmaceuticals International has a fifty-two week low of $35.20 and a fifty-two week high of $84.06. The company has a market capitalization of $5.69 billion, a PE ratio of 75.24 and a beta of 0.04.

Insiders Place Their Bets

In related news, CAO Michael R. Megna sold 4,600 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the sale, the chief accounting officer directly owned 29,062 shares in the company, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the sale, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The SEC filing for this sale provides additional information. 51.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of research analyst reports. Wells Fargo & Company began coverage on Kiniksa Pharmaceuticals International in a research note on Wednesday, September 30th. They issued an “overweight” rating and a $87.00 price target on the stock. Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Canaccord Genuity Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.14.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.